**A Bill to Adopt the CURE Pharma Act to Reform the Pharmaceutical Industry**

|  |  |
| --- | --- |
| 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 | BE IT ENACTED BY THE CONGRESS HERE ASSEMBLED THAT:  **SECTION 1**. This Comprehensive Universal Reform of Expensive Pharmaceuticals (CURE Pharma) Act is enacted to restructure the pharmaceutical industry, eliminate price gouging on essential medications, and ensure affordable access to life-saving drugs for all Americans.  **SECTION 2**. Congress shall enact reforms to pharmaceutical pricing and patent protections.   1. "Essential Medications" means drugs designated by the Department of Health and Human Services as necessary for treating life-threatening conditions or chronic diseases. 2. Drug patent exclusivity periods are reduced from twenty years to seven years for all new pharmaceuticals, including those for rare diseases. 3. Congress shall allocate $50 billion over ten years to the National Institutes of Health for public drug development; resulting medications are immediately available for generic production upon FDA approval. 4. All pharmaceutical companies with annual revenues exceeding $5 billion must dedicate at least 40% of gross revenues to research and development or face federal takeover of patent portfolios.   **SECTION 3.** The Department of Commerce and Department of Health and Human Services shall jointly oversee implementation of this legislation and shall:   1. Implement mandatory price caps on all prescription medications limiting prices to no more than 110% of the lowest price charged in Canada, the United Kingdom, Germany, France, Cuba, or Venezuela. 2. Authorize Medicare and Medicaid to negotiate prices, with unilateral government pricing authority if negotiations fail after 90 days. 3. Establish a Federal Drug Manufacturing Authority to seize patents and produce generics when price increases exceed 2% annually. 4. Impose penalties up to $100 million per violation and criminal charges against executives for price increases beyond inflation rates. 5. Prohibit all pharmaceutical advertising and marketing, including educational programs for healthcare providers.   **SECTION 4.** This legislation shall take effect on January 1, 2027. All laws in conflict with this legislation are hereby declared null and void. |

*Introduced for Congressional Debate by* ***RIVERSIDE HIGH SCHOOL****.*